Current diagnosis and management of XXXX .

@entity1 @entity43 @entity5 @entity42 @entity10224
The epidemiology of @entity42 is unclear due to the lack of consistent reporting and a high likelihood of spontaneous resolution. In the USA, postmenopausal @entity1 have an @entity42 incidence of 18% over a 15-year period. Worldwide, about 7% of @entity1 have an @entity42 at some point in their lives. In Europe, a large screening trial revealed a 21.2% incidence of @entity42 among healthy postmenopausal @entity1 . The American College of Obstetricians and Gynecologists (ACOG) stated that simple cysts found on ultrasound may be safely followed without intervention, even in postmenopausal @entity1 . These cysts are not likely @entity5 precursors, nor markers of increased risk, and can be managed conservatively. @entity42 appear to be stable or resolve by the next annual examination. These findings support recent recommendations to follow unilocular simple cysts in postmenopausal @entity1 without intervention. For those @entity1 , @entity43 screening and follow up include a @entity10224 blood test and transvaginal ultrasonography (TVU) at baseline, an annual TVU for three additional years, and annual @entity10224 tests for five years beyond baseline. The TVU screening examination is considered positive (abnormal and suspicious for @entity43 ) when findings included: 1) ovarian volume greater than 10 cubic cm; 2) cyst volume greater than ten cubic cm; 3) any solid area or papillary projection extending into the cavity of a @entity43 of any size; or, 4) any mixed (solid/cystic) component within a @entity43 . @entity1 with positive screening examinations are referred to gynecologic oncology unit for follow-up investigation. Diagnostic consideration and surgical management of @entity42 are discussed.
